Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Glaxo’s Diabetes Drug Recommended by EU Regulator

Jan. 24 (Bloomberg) -- GlaxoSmithKline Plc said Eperzan, its treatment for Type 2 diabetes, was recommended for approval by the European Union’s drug regulator.

The once-weekly medicine, also known as albiglutide, was recommended by the European Medicines Agency as a treatment to improve glycemic control in adults with Type 2 diabetes, Glaxo said in a statement today.

Clinical trials showed mixed results on albiglutide’s effectiveness and side effects. It hasn’t demonstrated benefits over Takeda Pharmaceutical Co.’s Actos or Novo Nordisk A/S’s Victoza, two leading diabetes treatments. Glaxo has said albiglutide’s once-weekly dosing would make the drug more convenient for patients compared with existing daily treatments.

“Eperzan’s commercial potential is still likely to be limited,” said Sam Fazeli, a Bloomberg Industries analyst in London.

Sales of albiglutide may reach $218 million by 2016, according to the average of seven analyst estimates compiled by Bloomberg.

Glaxo has also filed the drug with the U.S. Food and Drug Administration, which extended the review period by three months to April 15, the company said in August. Glaxo is seeking a partner in the U.S. to help market the drug.

The European agency’s recommendations are the final stage before the European Commission, the EU’s executive arm, approves or rejects a drug for sale to patients in the 28-nation region.

To contact the reporter on this story: Makiko Kitamura in London at

To contact the editor responsible for this story: Phil Serafino at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.